AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-0.1%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$210M
AUM Growth
+$210M
(+2.9%)
Cap. Flow
+$13.3M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
53.68%
Holding
85
New
10
Increased
25
Reduced
14
Closed
11
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$4.04M |
| 2 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
$3.84M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
$3.45M |
| 4 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$3.26M |
| 5 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$2.94M |
Top Sells
| 1 |
Travere Therapeutics
TVTX
|
$5.49M |
| 2 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
$2.96M |
| 3 |
Curis
CRIS
|
$2.82M |
| 4 |
Celldex Therapeutics
CLDX
|
$2.68M |
| 5 |
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
|
$2.5M |
Sector Composition
| 1 | Healthcare | 90.08% |
| 2 | Financials | 4.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
ARK Genomic Revolution ETF
ARKG
$1.05B
| – | – |
0
| – | – |
|
77
Alnylam Pharmaceuticals
ALNY
$58.6B
| – | – |
0
| – | – |
|
78
Vertex Pharmaceuticals
VRTX
$102B
| – | – |
0
| – | – |
|
79
Moderna
MRNA
$9.36B
| – | – |
0
| – | – |
|
80
Ionis Pharmaceuticals
IONS
$9.64B
| – | – |
0
| – | – |
|
81
Immunovant
IMVT
$2.91B
| – | – |
0
| – | – |
|
82
CureVac
CVAC
$1.21B
| – | – |
0
| – | – |
|
83
C4 Therapeutics
CCCC
$182M
| – | – |
-20,000
| Closed | -$740K |
|